✦ LIBER ✦

A multicentre prospective study on pemetrexed in the second line chemotherapy of non small cell lung cancer. Data from routine clinical practice

✍ Scribed by Kolek, Vítězslav; Pešek, Miloš; Grygárková, Ivona; Zatloukal, Petr; Skřičková, Jana; Sixtová, Dimka; Koubková, Leona; Roubec, Jaromír; Salajka, František; Petruželka, Luboš; Vyzula, Rostislav; Štícha, Michal

Book ID: 119320878
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 46 KB
Volume: 77
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2012.05.062

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Second-line Treatment of Stage III/IV No

Second-line Treatment of Stage III/IV Non-Small-Cell Lung Cancer (NSCLC) with pemetrexed in routine clinical practice: Evaluation of performance status and health-related quality of life

✍ Wolfgang Schuette; Hans Tesch; Hartwig Büttner; Thomas Krause; Victoria Soldaten 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 354 KB

Pemetrexed Versus Pemetrexed and Carbopl

Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial

✍ Ardizzoni, A.; Tiseo, M.; Boni, L.; Vincent, A. D.; Passalacqua, R.; Buti, S.; A 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 200 KB

Clinical assessment of patients with adv

Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: A prognostic score from individual data of nine randomised trials

✍ Massimo Di Maio; Nicola Lama; Alessandro Morabito; Egbert F. Smit; Vassilis Geor 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 433 KB

First-Line Erlotinib Followed by Second-

First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The TORCH Randomized Trial

✍ Gridelli, C.; Ciardiello, F.; Gallo, C.; Feld, R.; Butts, C.; Gebbia, V.; Maione 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 259 KB

21 The survival benefit of erlotinib in

21 The survival benefit of erlotinib in the management of advanced non-small cell lung cancer (NSCLC) in the routine clinical practice; a retrospective study

✍ Daverede, L.; Elmahdawi, N.; Scott, C.; Bozas, G.; Upadhyay, S.; Dhadda, A.; But 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 34 KB

P-337 The ACTION study of patients with

P-337 The ACTION study of patients with advanced non-small cell lung cancer (NSCLC) in routine clinical practice: A comparison of physician-versus patient-rated health status in 967 patients prior to first-line chemotherapy

✍ Pimentel, F.; Watkins, J.; Bhalla, S.; Riska, H.; Belger, M.; Anderson, H.; Thom 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 125 KB